prikaz prve stranice dokumenta Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
  Preuzmi
PDF 605.94 KB
Znanstveni rad - Izvorni znanstveni rad
Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
Biomedicines, 11 (2022), 1; 53. https://doi.org/10.3390/biomedicines11010053
Ivković, Irena; Limani, Zgjim; Jakovčević, Antonia; Gajović, Srećko; Seiwerth, Sven; Đanić Hadžibegović, Ana; Prgomet, Drago

Citirajte ovaj rad

Ivković, I., Limani, Z., Jakovčević, A., Gajović, S., Seiwerth, S., Đanić Hadžibegović, A. i Prgomet, D. (2022). Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer. Biomedicines, 11. (1). doi: 10.3390/biomedicines11010053

Ivković, Irena, et al. "Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer." Biomedicines, vol. 11, br. 1, 2022. https://doi.org/10.3390/biomedicines11010053

Ivković, Irena, Zgjim Limani, Antonia Jakovčević, Srećko Gajović, Sven Seiwerth, Ana Đanić Hadžibegović i Drago Prgomet. "Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer." Biomedicines 11, br. 1 (2022). https://doi.org/10.3390/biomedicines11010053

Ivković, I., et al. (2022) 'Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer', Biomedicines, 11(1). doi: 10.3390/biomedicines11010053

Ivković I, Limani Z, Jakovčević A, Gajović S, Seiwerth S, Đanić Hadžibegović A, i sur.. Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer. Biomedicines [Internet]. 26.12.2022. [pristupljeno 11.04.2024.];11(1). doi: 10.3390/biomedicines11010053

I. Ivković, et al., "Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer", Biomedicines, vol. 11, br. 1, Prosinac 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:847497. [Citirano: 11.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:847497
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
AutorIrena Ivković
AutorZgjim Limani
AutorAntonia Jakovčević
AutorSrećko Gajović
AutorSven Seiwerth
AutorAna Đanić Hadžibegović
AutorDrago Prgomet
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA HISTOLOGIJU I EMBRIOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA OTORINOLARINGOLOGIJU I KIRURGIJU GLAVE I VRATA)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOFIZIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Citologija, histologija i embriologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Otorinolaringologija
Sažetak (engleski)
The early-stage diagnosis of papillary thyroid cancer (PTC) has significantly increased in incidence worldwide without any beneficial impact on survival. In order to improve the risk assessment in PTC, we have conducted a retrospective study in which we analyzed the BRAF V600E mutation and CPSF2 protein expression as prognostic markers on archival tissue samples of 49 patients without (control group) and 97 patients with (study group) PTC metastases in the cervical lymph nodes at the time of initial diagnosis. Our aim was to correlate the BRAF V600E mutation and the expression of CPSF2 protein with the clinical and pathological features of PTC. The expression of CPSF2 protein was evaluated via immunohistochemistry and graded semi-quantitatively. The presence of the BRAF V600E mutation was determined via real-time polymerase chain reac-tion (PCR). CPSF2 protein < 3+ intensity expression was correlated with more frequent recurrences (Fisher-Freeman-Halton exact test; p = 0.010; 95% CI: 1.26−22.03), and patients who presented with the BRAF V600E mutation and CPSF2 protein expression < 3+ intensity had shorter disease-free survival (log-rank test; 105.0 months vs. 146.6 months; p < 0.001; HR 8.32, 95% CI: 2.91−23.83), whereas patients with PTC who had CPSF2 expression 3+ had longer disease-free survival in correlation with other lower intensity expressions of CPSF2 protein (log-rank test; 139.7 months vs. 129.6 months; p = 0.008). The multivariate analysis showed that younger patients with CPSF2 protein expression <3+ and the BRAF V600E mutation are at an increased risk for recurrence and require more intensive monitoring (Cox proportional hazards regression model; X2 = 17.5, df = 10, p = 0.025). Our results correlate the BRAF V600E mutation and CPSF2 protein expression with recurrence and disease-free survival as relevant prognostic factors for PTC.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 11, br. 1, 53
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines11010053
URN:NBNurn:nbn:hr:105:847497
Datum objave publikacije2022-12-26
URL dokumentahttps://www.mdpi.com/2227-9059/11/1/53
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-24 12:31:28